VestGen Advisors LLC Acquires 4,086 Shares of Axon Enterprise, Inc $AXON

VestGen Advisors LLC grew its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 144.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,912 shares of the biotechnology company’s stock after acquiring an additional 4,086 shares during the period. VestGen Advisors LLC’s holdings in Axon Enterprise were worth $5,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Trustmark Bank Trust Department bought a new position in Axon Enterprise in the 2nd quarter worth $635,000. Dilation Capital Management LP purchased a new stake in Axon Enterprise in the second quarter worth about $3,814,000. New York State Common Retirement Fund increased its position in Axon Enterprise by 4.4% in the second quarter. New York State Common Retirement Fund now owns 37,839 shares of the biotechnology company’s stock worth $31,328,000 after buying an additional 1,600 shares in the last quarter. West Family Investments Inc. bought a new position in shares of Axon Enterprise in the second quarter worth about $294,000. Finally, Williamson Legacy Group LLC lifted its position in shares of Axon Enterprise by 7.7% during the 2nd quarter. Williamson Legacy Group LLC now owns 2,511 shares of the biotechnology company’s stock valued at $2,079,000 after buying an additional 179 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $540.14 on Friday. The business’s 50-day moving average is $658.44 and its 200 day moving average is $726.85. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The company has a market capitalization of $42.62 billion, a P/E ratio of 133.37, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business’s revenue was up 30.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.45 EPS. On average, equities research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at $11,402,280. This represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brittany Bagley sold 2,500 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $610.00, for a total transaction of $1,525,000.00. Following the transaction, the chief financial officer owned 91,092 shares of the company’s stock, valued at $55,566,120. This trade represents a 2.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 38,622 shares of company stock worth $26,439,364. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on AXON. Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Piper Sandler dropped their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Barclays reduced their price objective on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. The Goldman Sachs Group lowered their target price on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $870.00 target price on shares of Axon Enterprise in a report on Wednesday, September 24th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus target price of $814.00.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.